Featured Research

from universities, journals, and other organizations

Alzheimer’s drug trials: Scientists learn from the old, bring on the new

Date:
November 20, 2012
Source:
Alzheimer Research Forum Foundation
Summary:
Potential Alzheimer’s disease drugs have performed poorly in clinical trials with no sign of any new approvals on the horizon. Have scientists reached a therapeutic dead end? Not according to experts.

Alzheimer's therapeutic trials have gotten bad press lately, but it is not all gloom and doom. As evident at the 5th Clinical Trials in Alzheimer's Disease (CTAD) conference, held 29-31 October in the Principality of Monaco, scientists keep extracting new data from recent drug trials to gear up for a round of new ones that aim to tackle Alzheimer's earlier than ever before. The Alzheimer Research Forum, an online resource specializing in Alzheimer's and related diseases, reported on event highlights.

At CTAD, the latest news on immunotherapies was most anticipated. Bapineuzumab and solanezumab are monoclonal antibodies that target Aβ, the principal component of the senile plaques found in brains of people with AD. Both fell short of their main goal in recent phase 3 trials. New data at CTAD confirms that solanezumab slowed mental decline up to 35 percent in the mildest group of patients. Bapineuzumab knocked down protein markers of brain cell death in the cerebrospinal fluid, but slightly hastened brain shrinkage. The hints of benefit for solanezumab offer hope for patients treated in early stages of the disease. Researchers continue to analyze both data sets to learn all they can about why these drugs failed in some aspects and succeeded in others (see Part 2). "These datasets are very large, and have more to tell us," said Paul Aisen of the University of California, San Diego.

Researchers also discussed the best ways to conduct trials targeting earlier stages of Alzheimer's, perhaps even before symptoms begin. The conference highlighted plans to refine the tools and designs necessary for this. Presenters pointed out the need to study younger age groups in clinical trials, because it is difficult to distinguish normal cognitive changes from those related to dementia in people over 85. Others suggested researchers administer cognitive tests more and avoid tests that people master with practice. Practice effects can make it difficult to separate improvements due to drugs over those that occur on placebo. (see Part 1).

For data analysis, some scientists are adopting Bayesian statistics -- the type that gained recent fame when it was used to correctly predict the U.S. Presidential election. This approach allows investigators to adapt trials as they are underway (see Part 4). Used successfully in cancer, adaptive methods could reveal the optimum dose of a drug by testing far fewer patients and in less time than is currently done, researchers say.

Alzforum's CTAD coverage highlights how drug regulatory agencies are evolving their stance on AD (see Part 3), trials of a new anti-inflammatory drug in people who are genetically at-risk of AD (see Part 5), the use of electroencephalography to monitor drug efficacy in trials, a sneak peak at European trials trying to prevent AD with lifestyle changes (see Part 6), and a look at the possible health economics of a goal researchers have been after, that is, a treatment that slows the course of AD, not just its symptoms.

Alzforum's seven-part series published beginning on November 8, 2012, is freely available on the ARF website.


Story Source:

The above story is based on materials provided by Alzheimer Research Forum Foundation. Note: Materials may be edited for content and length.


Cite This Page:

Alzheimer Research Forum Foundation. "Alzheimer’s drug trials: Scientists learn from the old, bring on the new." ScienceDaily. ScienceDaily, 20 November 2012. <www.sciencedaily.com/releases/2012/11/121120152319.htm>.
Alzheimer Research Forum Foundation. (2012, November 20). Alzheimer’s drug trials: Scientists learn from the old, bring on the new. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2012/11/121120152319.htm
Alzheimer Research Forum Foundation. "Alzheimer’s drug trials: Scientists learn from the old, bring on the new." ScienceDaily. www.sciencedaily.com/releases/2012/11/121120152319.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins